27.7 C
New York
Friday, June 5, 2026

Tag: bench

newssourceFORcompanyinformationcontent1marketreleases

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

IDBS i3 2026 forum in Boston showcases real-world customer outcomes in data-driven BioPharma

WOKING, United Kingdom, June 4, 2026 /PRNewswire/ -- IDBS, a Danaher company and leading provider of cloud software for BioPharma organizations, today shared outcomes from...

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

New High-grade Lithium, Caesium, and Tantalum Pegmatite Discoveries in Surface Exploration Works

PMET's premier James Bay - Quebec geology delivers further exploration success with 2.94% Li2O, 16.43% Cs2O, and 3,768ppm Ta2O5 in surface samples at its...

New High-grade Lithium, Caesium, and Tantalum Pegmatite Discoveries in Surface Exploration Works

PMET's premier James Bay - Quebec geology delivers further exploration success with 2.94% Li2O, 16.43% Cs2O, and 3,768ppm Ta2O5 in surface samples at its...

New High-grade Lithium, Caesium, and Tantalum Pegmatite Discoveries in Surface Exploration Works

PMET's premier James Bay - Quebec geology delivers further exploration success with 2.94% Li2O, 16.43% Cs2O, and 3,768ppm Ta2O5 in surface samples at its...

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

Fermi America™ Names Two Highly Successful Nuclear Developers, Mesut and Sezin Uzman, to Spearhead Nuclear Power Delivery

- Seasoned global leaders have successfully supported 16 landmark nuclear projects across the UAE and China - Fermi America bringing global "Power Couple" home to...

Granite Asia Strengthens Multi-Asset Leadership with Appointment of Three New Managing Partners

SINGAPORE, Aug. 12, 2025 /PRNewswire/ -- Granite Asia today announced the appointment of three new Managing Partners, further strengthening the firm's leadership across equity...

Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR

FLINT Announces Transformational Recapitalization

CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- FLINT Corp. ("FLINT" or the "Company") (TSX: FLNT) is pleased to announce a proposed recapitalization transaction (the "Recapitalization") that will significantly reduce the Company's debt and annual interest costs, simplify its capital structure and improve liquidity. The Recapitalization is the result of an extensive review process conducted by the Company's board of directors (the "Board"), which culminated in FLINT entering into a definitive recapitalization support agreement (the "Support Agreement") with its largest shareholder and primary lender, Canso Investment Counsel Ltd., in its capacity as portfolio manager for and on behalf of certain accounts that it manages ("Canso"). The Recapitalization is intended to preserve value for the Company's shareholders and better position FLINT to execute on future growth opportunities.

BDC Laboratories Partners with Newly Launched Dilawri Cardiovascular Institute to Advance Clinically Relevant Cardiovascular Device Testing

Strategic collaboration supports cutting-edge translational research, combining regulatory-grade bench testing with clinical insight to improve outcomes for patients. WHEAT RIDGE, Colo. and VANCOUVER, BC, Aug....

BDC Laboratories Partners with Newly Launched Dilawri Cardiovascular Institute to Advance Clinically Relevant Cardiovascular Device Testing

Strategic collaboration supports cutting-edge translational research, combining regulatory-grade bench testing with clinical insight to improve outcomes for patients. WHEAT RIDGE, Colo. and VANCOUVER, BC, Aug....

EnerCom Announces Andrew Rapp, Senior Advisor in the U.S. Department of Energy, as Keynote Speaker on August 18th at EnerCom’s 30th Anniversary Energy Investment...

Qualified Investors and Analysts Can Register at No Cost at  www.enercomdenver.com Deadline to Submit One-on-One Meeting Requests to Presenting Companies is Friday, August 8th  Registration still...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBench

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers